pressor

Losartan Carboxylic Acid (E-3174) 是 Losartan 的活性羧酸代谢产物，是血管紧张素Ⅱ受体 1 型(AT1)拮抗剂。它能够阻断血管紧张素 II 诱导的血管平滑肌细胞反应，可以提高血浆肾素活性，降低平均动脉压。

Lac repressor fragment 33-38 Lys-Arg-Glu-Lys-Val fragment from lac repressor.

p53 tumor suppressor fragment (232-240) is a peptide with the sequence H2N-Lys-Tyr-Met-Cys-Asn-Ser-Ser-Cys-Met-OH, MW= 1066.3. p53 is a tumor suppressor protein that in humans is encoded by the TP53 gene. p53 is crucial in multicellular organisms, where i

Glycyl-L-Histidyl-L-Lysine 是一种肝细胞生长因子和一种合成的肝营养剂，可刺激肝红细胞生成因子的产生。

Metaraminol tartrate (Metaradrine tartrate) 是一种 α-肾上腺素能 (α-adrenergic) 激动剂，是一种直接或间接影响肾上腺素受体的拟交感神经胺，其中 α 效应占主导地位，可作为血管加压剂。

Ubiquitination-IN-1 是一种有效的泛素化和Cksl-Skp2蛋白互作抑制剂 (IC50=0.17 μM) 抑制剂，增加 p27 水平，可通过阻断肿瘤抑制因子的降解发挥作用。

BCL6-IN-8c is an orally active and potent inhibitor of B-cell lymphoma 6 (BCL6)-corepressor interaction(IC50 of 0.10 μM in cell-free enzyme-linked immunosorbent assay).

Nanaomycin A 是一种醌类抗生素，可重新激活人类癌细胞中沉默的肿瘤抑制基因。 Nanaomycin A 是 DNMT3B 的特异性抑制剂 (IC50 = 500 nM)。

NSC622608 是 V 域 Ig 抑制 T 细胞活化 (VISTA) 的小分子配体，VISTA 是影响 T 细胞攻击肿瘤能力的免疫检查点。

Metoprolol fumarate (CGP 2175C)，为一种具口服活性、选择性β1-肾上腺素受体 (β1-adrenoceptor) 拮抗剂，展现抗炎、抗肿瘤及抗血管生成特性。

Onvatilimab (JNJ-61610588) 是一种人 IgG1κ 抗 VISTA (T 细胞激活的 V 域 Ig 抑制剂) 单克隆抗体。Onvatilimab 具有抗肿瘤活性，可用于治疗晚期头颈癌。 。

viFSP1为跨物种的FSP1抑制剂，能诱发FSP1依赖的细胞铁死亡(ferroptosis)。该化合物通过靶向FSP1上的高度保守的NAD(P)H结合口袋，直接作用于FSP1，从而抑制其活性。此外，viFSP1还能促进脂质过氧化，显示出潜在的抗癌效果。

SX-682 是口服有效的 CXCR1和 CXCR2变构抑制剂，可以阻断肿瘤髓系抑制细胞募集并增强 T 细胞活化和抗肿瘤免疫，具有治疗去势抵抗性前列腺癌的潜力。

Hamamelitannin 是分离自 Hamamelis virginiana 树皮的一种多酚，是群体感应抑制剂。它通过影响肽聚糖生物合成和 eDNA 释放增加金黄色葡萄球菌生物膜的抗生素敏感性。

N6-Cyclohexyladenosine (CHA) 是一种选择性腺苷 A1 受体激动剂，EC50 为 8.2 nM。

Human Big ET-1 comprises residues 53-90 of the endothelin precursor (preproendothelin). Compared to the mature endothelin-1 (hET-1), the peptide show less vasoconstrictor activity in vitro, but similar pressor effects in vivo. Former CAS-number 121014-53-7.

The big endothelins comprise residues 53-90 (human big ET-1) and 53-91 (porcine big ET-1) of the endothelin precursor (preproendothelin). Compared to the mature endothelin-1 (ET-1), both peptides show less vasoconstrictor activity in vitro, but similar pressor effects in vivo. Former CAS-number 121014-54-8.

Urotensin II is a peptide vasoconstrictor and agonist of the urotensin (UT) receptor (Ki= 2.06 nM for the human recombinant receptor expressed in HEK293 cells).1It stimulates intracellular calcium mobilization in HEK293 cells expressing human and rat UT (EC50s = 0.47 and 0.78 nM, respectively) but decreases intracellular calcium concentration in goby (G. mirabilis) enterocytes when used at a concentration of 500 nM.2Urotensin II (20 mU/ml) stimulates active sodium and chloride absorption across isolated goby posterior intestine in 5% seawater-adapted solution.3In vivo, urotensin II (1.5-150 nmol/kg) decreases diastolic blood pressure and increases heart rate in anesthetized rats.4It also reduces the pressor responses to sympathetic nerve stimulation, norepinephrine , and vasopressin in pithed rats when administered at a dose of 150 nmol/kg. 1.Ames, R.S., Sarau, H.M., Chambers, J.K., et al.Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14Nature401(6750)282-286(1999) 2.Loretz, C.A., and Assad, J.A.Urotensin II lowers cytoplasmic free calcium concentration in goby enterocytes: Measurements using quin2Gen. Comp. Endocrinol.64(3)355-361(1986) 3.Loretz, C.A., Freel, R.W., and Bern, H.A.Specificity of response of intestinal ion transport systems to a pair of natural peptide hormone analogs: Somatostatin and urotensin IIGen. Comp. Endocrinol.52(2)198-206(1983) 4.Gibson, A., Wallace, P., and Bern, H.A.Cardiovascular effects of urotensin II in anesthetized and pithed ratsGen. Comp. Endocrinol.64(3)435-439(1986)

The alpha-adrenoceptors blocking effect of (N-piperidinomethyl)-2-chromanne was studied in vivo and in vitro in the rat. In the pithed rat, (N-piperidinomethyl)-2-chromanne (1 mg/kg i.v.) antagonized the pressor effects induced by alpha agonists. (N-piperidinomethyl)-2-chromanne competitively antagonized the pressor effects of M7 (alpha 2-agonist) and cirazoline (alpha 1-agonist). (N-piperidinomethyl)-2-chromanne antagonized the inhibitory effects of clonidine on presynaptic alpha 2-receptors in stimulated pithed rats.

Pentoprilat is a member of a series of l-glutarylindoline-2(S)-carboxylic acid derivatives. Pentopril was evaluated as an inhibitor of a cell-free preparation of angiotensin-converting enzyme (ACE) isolated from rabbit lung. Intravenous administration of incremental doses of pentopril to anesthetized normotensive rats produced a dose-related inhibition of angiotensin I (AI) pressor responses. The onset of inhibition of the A1 pressor response was rapid, and substantial inhibition occurred at 5 min after administration of the ACE inhibitors. Pentopril hydrolyzed in vivo to the biologically active free-acid form of CGS 13934. It was well tolerated in normal volunteers and hypertensive patients. Pentopril was developed for the treatment of both hypertension and congestive heart failure. Pentopril produced little clinical improvement and no biochemical improvement in a patients with rheumatoid arthritis.

FRAN-12 is a histamine and 5-hydroxytryptamine antagonist with pressor properties.

Quinapril-d5 is intended for use as an internal standard for the quantification of quinapril by GC- or LC-MS. Quinapril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor quinaprilat. In vivo, quinapril reduces mean arterial pressure in renal hypertensive and spontaneously hypertensive rats. It inhibits angiotensin I-induced pressor responses in normotensive rats and dogs. Quinapril prevents left ventricular heart failure in CHF 14.6 cardiomyopathic hamsters. Formulations containing quinapril have been used in the treatment of hypertension, heart failure, and diabetic nephropathy.

Fosinopril-d7 is intended for use as an internal standard for the quantification of fosinopril by GC- or LC-MS. Fosinopril is a prodrug form of the angiotensin-converting enzyme inhibitor fosinoprilat. Oral administration of fosinopril inhibits angiotensin I-induced pressor responses in normotensive rats, dogs, and monkeys when administered at doses of 15, 15, and 10 µmol/kg, respectively. Fosinopril reduces fractional shortening and decreases left ventricular size in a porcine model of congestive heart failure. Formulations containing fosinopril have been used in the treatment of hypertension and congestive heart failure.

Gepefrine为具口服活性的升压剂及拟交感神经作用剂，能有效改善动脉压早期直立性失调。